Detalles de la búsqueda
1.
The effect of acquired cisplatin resistance on sensitivity to EGFR tyrosine kinase inhibitors in EGFR mutant lung cancer cells.
Oncol Res
; 19(10-11): 471-8, 2011.
Artículo
en Inglés
| MEDLINE | ID: mdl-22715590
2.
Correction: Role of IGF-Binding Protein 3 in the Resistance of EGFR Mutant Lung Cancer Cells to EGFR-Tyrosine Kinase Inhibitors.
PLoS One
; 14(3): e0213984, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-30870512
3.
Multiple resistant factors in lung cancer with primary resistance to EGFR-TK inhibitors confer poor survival.
Lung Cancer
; 88(2): 139-46, 2015 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-25724261
4.
Clinical significance of NQO1 polymorphism and expression of p53, SOD2, PARP1 in limited-stage small cell lung cancer.
Int J Clin Exp Pathol
; 7(10): 6743-51, 2014.
Artículo
en Inglés
| MEDLINE | ID: mdl-25400754
5.
Autophagosome-mediated EGFR down-regulation induced by the CK2 inhibitor enhances the efficacy of EGFR-TKI on EGFR-mutant lung cancer cells with resistance by T790M.
PLoS One
; 9(12): e114000, 2014.
Artículo
en Inglés
| MEDLINE | ID: mdl-25486409
6.
Role of IGF-binding protein 3 in the resistance of EGFR mutant lung cancer cells to EGFR-tyrosine kinase inhibitors.
PLoS One
; 8(12): e81393, 2013.
Artículo
en Inglés
| MEDLINE | ID: mdl-24339922
Resultados
1 -
6
de 6
1
Próxima >
>>